CYP2C19 intermediate and poor metabolizer statuses may be associated with coronary atherosclerosis among patients with type 2 diabetes mellitus. [PDF]
Cai N +6 more
europepmc +1 more source
Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. [PDF]
Byoun S +7 more
europepmc +1 more source
Protracted escitalopram discontinuation syndrome and serotonin toxicity associated with CYP2C19 poor metabolism: A case report. [PDF]
Tran EH +4 more
europepmc +1 more source
Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. [PDF]
Etkins J +11 more
europepmc +1 more source
Exploring the Effect of Genetic Testing on Personalised Treatment Plans for Depression. [PDF]
Li S, Peng L, Wang Y.
europepmc +1 more source
CYP2C:TG Haplotype in Native Mexicans, Molecular Ancestry and Its Implications for CYP2C19 Genotype-Phenotype Correlation. [PDF]
de la Cruz CG +9 more
europepmc +1 more source
CYP2C19 genotype and cardiovascular events.
Siasos, Gerasimos +2 more
openaire +4 more sources
Comments on: "Association of Clopidogrel Genetic Polymorphism With Efficacy and Safety for Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Updated Meta-Analysis". [PDF]
Sah SS, Kumbhalwar A.
europepmc +1 more source

